IL6 and neoplasm: Zaidi et al. (2021) evaluated ADU-S100 anticarcinoma effect on esophageal adenocarcinoma, which is a STING agonist. The tumor volume in the ADU-S100 and ADU-S100 plus irradiation groups decreased by 30.1 and 50.8%, respectively, and the tumor volume in the placebo group and placebo plus irradiation group increased by 76.7 and 152.4%, respectively. INFβ tumor necrosis factor-α IL-6 and CCL-2 were significantly upregulated in the treatment group compared with placebo. Currently, ADU-S100 is being evaluated in clinical trials (NCT03172936) (Zaidi et al., 2021).